Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine

201648 citationsJournal Articlediamond Open Access

Authors

Fateme Gableh · Golestan University

Mohsen Saeidi · Golestan University

Shaghayegh Hemati · Islamic Azad University Rasht Branch

Kasra Hamdi · Islamic Azad University of Shiraz

Hoorieh Soleimanjahi · Tarbiat Modares University

Ali Gorji · University of Münster

Amir Ghaemi ·

Abstract

The strong adjuvanticity associated with α-GalCer/MPL combination may to be an important tool in the development of novel and strong cancer immunotherapy.

Topics & Keywords

Immunotherapy and Immune Responses Immune Cell Function and Interaction Immune Response and Inflammation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Biomedical Science

Volume 23, Issue 1, pp. 16-16

DOI: 10.1186/s12929-016-0238-3

Field-Weighted Citation Impact: 3.26